A better understanding of the molecular drivers of tumor progression and recurrence, such as the roles of NF2, SMO, AKT1, TRAF7, and KLF4 mutations, will facilitate the development of targeted therapies, potentially improving outcomes for patients with atypical and anaplastic meningiomas [45]. Here, KLF4 is linked to meningioma.